Monoamine-depleting agents are a group of drugs which reversibly deplete one or more of the monoamine neurotransmitters – serotonin, dopamine, and norepinephrine. One mechanism by which these agents act is by inhibiting reuptake by the vesicular monoamine transporters, VMAT1 and VMAT2. Examples of monoamine-depleting agents include deutetrabenazine, oxypertine, reserpine, tetrabenazine, and valbenazine. Tetrabenazine selectively depletes dopamine at low doses and is used as an animal model of amotivation.
See also
- Monoamine neurotoxin
- Monoamine reuptake inhibitor
- Monoamine releasing agent
- Tetrabenazine § Animal model of motivational dysfunction
References
- ^ Carlsson A (1975). "Monoamine-depleting drugs". Pharmacol Ther B. 1 (3): 393–400. doi:10.1016/0306-039x(75)90045-8. PMID 772709.
- ^ Vijayakumar D, Jankovic J (May 2016). "Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia". Drugs. 76 (7): 779–87. doi:10.1007/s40265-016-0568-1. PMID 27091214. S2CID 13570794.
- ^ Guay DR (August 2010). "Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders". Am J Geriatr Pharmacother. 8 (4): 331–73. doi:10.1016/j.amjopharm.2010.08.006. PMID 20869622.
- Callaghan CK, Rouine J, O'Mara SM (2018). "Potential roles for opioid receptors in motivation and major depressive disorder". Prog Brain Res. 239: 89–119. doi:10.1016/bs.pbr.2018.07.009. PMID 30314570.
- Salamone JD, Correa M, Ferrigno S, Yang JH, Rotolo RA, Presby RE (October 2018). "The Psychopharmacology of Effort-Related Decision Making: Dopamine, Adenosine, and Insights into the Neurochemistry of Motivation". Pharmacol Rev. 70 (4): 747–762. doi:10.1124/pr.117.015107. PMC 6169368. PMID 30209181.